Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M

From Xconomy VC, Deals, & Startups
January 8, 2017 - 11:10pm
Merrimack Pharmaceuticals is starting off the year with significant changes. The Cambridge, MA, company has decided to sell its only marketed products—a pair of cancer drugs—to pay off debt and invest in a new set of experimental medicines. French pharmaceutical company Ipsen has bought Merrimack’s rights to the nanoparticle pancreatic cancer drug Onivyde and its […]

Continue reading this article »